Welcome to our dedicated page for Intercure Ltd. news (Ticker: INCR), a resource for investors and traders seeking the latest updates and insights on Intercure Ltd. stock.
InterCure Ltd. (INCR), also known as InterCure (dba Canndoc), is a pharmaceutical cannabis company focused on GMP-certified, pharma-grade medical cannabis. This news page aggregates company announcements, press releases and market updates so readers can follow how InterCure’s vertically integrated seed-to-sale model and international partnerships develop over time.
News items commonly include financial results, where InterCure reports revenue, Adjusted EBITDA and cash metrics for periods such as full fiscal years and half years. These releases often discuss the performance of its cannabis segment, the impact of external events on operations, and the role of compensation from Israeli authorities related to war-damaged facilities.
Another major category is strategic transactions and partnerships. InterCure has announced the strategic acquisition of Botanico Ltd. (ISHI), a premium medical cannabis technology and brand company with partnerships with leading American cannabis operators, and a strategic investment and collaboration with Cannasoul R&D Ltd. focused on evidence-based cannabis therapeutics. Additional news covers the expansion of its partnership with the Cookies brand into Germany and other European markets, as well as agreements to cultivate, manufacture, import and distribute branded products through EU-GMP facilities and licensed pharmacies.
Corporate governance and financing developments also appear in the news feed, such as changes in board leadership, private placement financings, loans from Israeli banks and participation in industry conferences. For investors and observers tracking the pharmaceutical cannabis sector, this page provides a centralized view of InterCure’s operational updates, strategic moves and regulatory disclosures over time.
Cookies announces a partnership with InterCure to expand into Europe, establishing retail locations in Austria and the U.K. in early 2022. This multiyear agreement allows InterCure to utilize its international supply chain to provide Cookies-branded products in these markets. Both companies aim to deliver quality cannabis products to the growing medical cannabis community. Cookies plans to enhance its brand presence internationally, leveraging its recognized status in the cannabis industry.
InterCure Ltd (NASDAQ: INCR) announces participation in Cowen’s 4th Annual Cannabis Conference from November 29 - December 1, 2021. CEO Alexander Rabinovitch will join the ‘International’ panel on November 30 at 11:50 a.m. ET. The event is virtual, allowing management to hold one-on-one meetings with institutional and corporate clients. InterCure, operating as Canndoc, is Israel's largest licensed cannabis producer and a leader in the rapidly growing cannabis market outside North America.
InterCure reported a remarkable third quarter in 2021, achieving a record revenue of $25 million, a 36% increase sequentially and threefold growth year-over-year. With an annualized revenue run rate of $100 million and an adjusted EBITDA run rate of $23 million, the company demonstrated strong operational performance. Cash flow from operations reached $4 million, marking five consecutive quarters of positive cash flow. The company expects continued growth through 2022, driven by strategic expansions and a solid cash reserve of $85 million.
InterCure has expanded its GIVOL pharmacy chain by adding four new locations in Israel, totaling 20 pharmacies. This move strengthens its market position in the pharmaceutical-grade medical cannabis sector, with 14 pharmacies licensed to dispense medical cannabis. In October 2021, InterCure achieved a record of one ton of medical cannabis products dispensed in a month, capturing about 30% of Israel's medical cannabis market. The company aims to enhance patient access to medical cannabis and expand its operations globally.
InterCure (NASDAQ: INCR) is set to release its third-quarter financial results on November 16, 2021, before the market opens. A conference call will follow at 8:30 AM ET, discussing the results and the company's growth strategy. InterCure, operating under the brand Canndoc, is Israel's largest licensed cannabis producer and claims to be the fastest-growing cannabis company outside North America. The firm has a vertically integrated model, ensuring high-margin operations.
InterCure (NASDAQ: INCR) announced a record revenue of CAD$24 million for Q3 2021, marking a 36% increase from Q2 and tripling the revenue compared to Q3 2020. This achievement marks the seventh consecutive quarter of double-digit revenue and high-digit profitable growth. The CEO purchased over CAD$3.7 million worth of shares, reflecting confidence in the company. With over CAD$78 million in cash, InterCure is well-positioned for expansion in both domestic and international markets, supported by the anticipated legalization of adult-use cannabis in Israel.
InterCure Ltd (NASDAQ: INCR) announced that CEO Alexander Rabinovitch will present at the Benzinga Cannabis Capital Conference on October 14, 2021, at 1:50 PM ET, with a repeat on October 15 at the same time. Additionally, he will participate in a panel discussion on the expansion of cannabis in European markets on October 15 at 2:10 PM ET. Interested attendees can view the presentation and panel online. InterCure, operating as Canndoc, is Israel’s largest licensed cannabis producer and is recognized for its GMP-certified medical cannabis products.
InterCure Ltd (NASDAQ: INCR) announced that CEO Alexander Rabinovitch bought 423,501 shares of the company's common stock in September 2021 at an average price of USD $7.03 per share, totaling USD $2,975,730. These purchases were made on NASDAQ and the Tel Aviv Stock Exchange. InterCure, operating as Canndoc, is Israel's largest licensed cannabis producer and one of the fastest-growing cannabis companies outside North America, leveraging a high-margin, vertically integrated model and robust distribution network.
InterCure Ltd (NASDAQ: INCR) will present live at VirtualInvestorConferences.com on September 9, 2021, at 11:30 AM ET. During this interactive event, investors can ask questions in real-time. Archived webcasts will be available post-event. InterCure is a leading, profitable cannabis operator outside North America, with its subsidiary Canndoc being Israel's largest licensed cannabis producer. The company recently reported Q2 '21 revenue growth of 400% YoY and signed an agreement to acquire strategic assets from Cannomed.
InterCure achieved record revenue of NIS 45 million (over CAD$17 million) in Q2 2021, marking a 400% year-over-year increase and a 37% rise compared to Q1 2021. The company reported an EBITDA of NIS 12 million ($5 million) and a margin of 26%. With a strong cash position of NIS 201 million ($78 million), positive operational cash flow was maintained for the fourth consecutive quarter. Revenue growth is anticipated to continue into Q3 and beyond, supported by market expansion and the introduction of new product lines like Cookies™. The acquisition of Better is also in progress, expected to strengthen market leadership.